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Abstract
Background: Persistent high risk HPV infection can lead to cervical cancer, the second most
common malignant tumor in women worldwide. NK cells play a crucial role against tumors and
virus-infected cells through a fine balance between activating and inhibitory receptors. Expression
of triggering receptors NKp30, NKp44, NKp46 and NKG2D on NK cells correlates with cytolytic
activity against tumor cells, but these receptors have not been studied in cervical cancer and
precursor lesions. The aim of the present work was to study NKp30, NKp46, NKG2D, NKp80 and
2B4 expression in NK cells from patients with cervical cancer and precursor lesions, in the context
of HPV infection.
Methods: NKp30, NKp46, NKG2D, NKp80 and 2B4 expression was analyzed by flow cytometry
on NK cells from 59 patients with cervical cancer and squamous intraepithelial lesions. NK cell
cytotoxicity was evaluated in a 4 hour CFSE/7-AAD flow cytometry assay. HPV types were
identified by PCR assays.
Results: We report here for the first time that NK cell-activating receptors NKp30 and NKp46
are significantly down-regulated in cervical cancer and high grade squamous intraepithelial lesion
(HGSIL) patients. NCRs down-regulation correlated with low cytolytic activity, HPV-16 infection
and clinical stage. NKG2D was also down-regulated in cervical cancer patients.
Conclusion: Our results suggest that NKp30, NKp46 and NKG2D down-regulation represent an
evasion mechanism associated to low NK cell activity, HPV-16 infection and cervical cancer
progression.
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Cervical cancer is the second most common female malig-
nant neoplasm worldwide. Human papillomavirus
(HPV) is a necessary but not sufficient cause of cervical
cancer. Co-factors that increase the risk for cervical cancer
among HPV-DNA positive women, include oral contra-
ceptives, smoking, high parity, previous sexually transmit-
ted disease and immunodeficiency [1]. Cervical
carcinogenesis implies HPV infection, viral persistence,
progression and invasion [2]. Both innate and adaptive
immune responses play a complex role against HPV infec-
tion. Spontaneous regression of high grade squamous
intraepithelial lesions due to HPV-16 infection is associ-
ated with HPV-16 E7 peptide-specific CD4+ T-cell
response and with lymphoproliferative responses to E2
plus IFN-gamma production [3-7]. However, innate
immune response acts directly or indirectly against viral
agents, through TLRs activation, dendritic cell presenta-
tion and NK cell function at cervical tissue level [8-11].
NK cells represent the first line of defense against viral
pathogens, killing infected cells or via secretion of
cytokines and chemokines [12]. There is also accumulat-
ing evidence for the crucial role of NK cells in tumor
immunosurveillance [13]. NK cell activation and tumor
lysis occur through a complex interaction between trigger-
ing receptors such as NKp30, NKp44, NKp46 and NKG2D
with tumor cell ligands, in fine balance with inhibitory
receptors and co-receptors [14]. Recently, it has been
reported that activating NK cell receptor ligands MICA
(NKG2D ligand) and CD155 (DNAM-1 ligand) are differ-
entially expressed during the progression to cervical can-
cer [15]. However, the expression of NKp30, NKp46,
NKG2D (triggering receptors) and co-receptors (NKp80
and 2B4) in NK cells from patients with cervical cancer
and precursor lesions remains unknown. The aim of the
present work was to study NKp30, NKp46, NKG2D,
NKp80 and 2B4 expression in NK cells from patients with




Blood samples were obtained from patients with invasive
squamous cervical carcinoma (20), high grade squamous
intraepithelial lesions (HGSIL) (20) and low grade squa-
mous intraepithelial lesions (LGSIL) (19). Colposcopy
and cytology results were confirmed by histopathology.
Two different pathologists independently confirmed the
diagnosis for all the specimens. Women without a history
of abnormal Pap smears and negative for HPV were
included as controls. Demographic, clinical characteristics
and epidemiologic data were obtained. All women were
attended at OPD Hospital Civil de Guadalajara, Mexico.
The protocol was approved by Biomedicine Sciences and
Ethic Committees (CSIM 200-22, 20000302032 and
2003, 259-0021), according to the last guidelines of the
World Medical Association Declaration of Helsinki.
Informed Consent was obtained from all participants
enrolled in the study.
Activating receptors (NKp30, NKp46 and NKG2D) and co-
receptors (CD80 and 2B4) evaluation
Peripheral blood mononuclear cells (PBMC) were iso-
lated by gradient Lymphoprep (Oslo Norway
Nycomed™). NK cells were obtained by immunomagnetic
negative selection (NK cell isolation kit, Miltenyi Biotec)
in accordance with the manufacturer's instructions. After
immunomagnetic depletion, NK cell CD56+ were >95%,
(confirmed by flow cytometry analysis). Cell concentra-
tion was adjusted to 1 × 105 and cells were incubated at
4°C for 30 min with proper dilution of anti-NKG2D
(ECM217), anti-NKp30 (Z25); anti-NKp46 (BAB281),
anti-NKp80 (MA252), or anti-2B4 (PP35) specific anti-
bodies (kindly donated by Professor Alessandro Moretta,
University of Genova, Italy). Cells were washed with a
phosphate buffered saline (PBS) solution and incubated
at 4°C for 30 min (in the dark) with FITC goat anti-mouse
secondary Ab (IgG1). The cells were washed twice and
incubated with 5 μL of PE-conjugated anti-CD56, PC5-
conjugated anti-CD3 mAbs or with control isotype and
fixed with 0.05% formaldehyde solution (all reagents
from Beckman Coulter). The percentages and Median Flu-
orescence Intensity (MFI) were determined with a proper
protocol and controls to compensate electronically for
overlapping signals, using an EPICS XL-MCL flow cytom-
eter (Beckman Coulter™).
NK cell cytotoxicity assay
NK cell cytotoxicity against K562 cells was evaluated in a
4 hours CFSE/7-AAD flow cytometry assay [16]. NK cells
were isolated from PBMC by cell sorting with anti-CD56
using FACSAria Cell Sorter (BD Bioscience). NK cell gate
was set based on their forward/sideward light scatter and
CD56/CD3 expression. The purity of the NK cells fraction
was ≥ 98%. NK cells were labeled with 5–6-carboxyfluo-
rescein diacetate succinimidyl ester (CSFE 200 nM) in
PBS/1% BSA for 15 min at 37°C. CFSE-labeled NK cells
were washed twice with PBS and seeded with a constant
number of K562 cells (20,000) at different E:T ratios (1:1,
3:1, 10:1. 30:1). Target cells were incubated alone to
measure basal cell death. Target cells and NK cells were
incubated in complete medium for 4 hours in a 5% CO2
atmosphere at 37°C. Cells were washed twice in PBS-1%
BSA containing 0.1% sodium azide (NaN3) and incubated
in the same buffer plus 20 μL/mL to 7-amino actinomycin
D (7-AAD, BD Biosciences) during 15 min at 4°C in dark-
ness. Acquisition was performed with the FACS Diva Soft-
ware (BD Bioscience). Cytotoxic activity was expressed as
% Specific Lysis calculated by the following formula:Page 2 of 8
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DNA extraction was done in cervical cells obtained by
cytobrush. Pellets containing cervical cells were obtained
by centrifugation at 10 000 rpm for 3 min, 200 μg of Pro-
teinase K was added for 48 hours at 37°C. Proteinase K
was inactivated at 94°C for 10 minutes. Aqueous superna-
tant was transferred to another fresh microtube. DNA was
precipitated by adding 100% ethanol and 20 mg/mL gly-
cogen (Sigma) for 30 min at 22°C. The pellet was washed
twice with 70% ethanol, dried, resuspended in 200 μL dis-




HPV typification was performed using specific primers
(Table 1). All PCR reactions were performed in a total vol-
ume of 50 mL. PCR mixture contained 75 mM Tris-HCl
pH 8.8, 20 mM (NH4)2SO4, 0.01% Tween 20, 2 mM
MgCl2, 0.2 mM dNTPs, 0.6 mM of each primer, 1.25 U
Taq DNA recombinant polymerase (Fermentas Interna-
tional Inc; Burlington, ON, Canada), and 100 ng DNA.
Genomic DNA from SiHa (HPV16) and HeLa (HPV18)
cells, tissue samples with known HPV infection for HPV6/
11, HPV31, and 33, were used as positive controls.
Genomic DNA from C33A cervical carcinoma cells was
used as negative control. The cycling protocol for CpI/
CPII was 94°C for 30 sec, 51°C for 30 sec, and 72°C for
60 sec for 40 cycles; HPV-16, 92°C for 120 sec, 48°C for
90 sec; HPV-6/11 and HPV-18, 92°C for 120 sec, 48°C for
90 sec, and 72°C for 60 sec for 38 cycles; and HPV-31 and
HPV-33, 94°C for 60 sec, 45°C for 60 sec, and 72°C for
60 sec for 45 cycles. Amplification products were electro-
phoresed on a 1.8% agarose gel and visualized after ethid-
ium bromide staining under UV light.
Statistical analysis
Statistical analysis was performed using the SPSS software
package version 10.0 (SPSS, Inc Chicago, IL). Data were
expressed as percentage, mean median fluorescence inten-
sity (MFI) and analyzed by ANOVA. Significance was
tested by non parametric test (Mann-Whitney U test). Dif-
ferences were considered statistically significant when the
p value was < 0.05. Spearman correlation was done to cor-
relate activating receptors with HPV expression and Pear-
son correlation to cytotoxic activity.
Results
The study enrolled 59 patients and 20 healthy women.
Histological analysis confirmed that cervical cancer
patients (20 cases) had squamous cell carcinomas (70%
non-keratinizing large cell type and 30% keratinizing
large cell type). HGSIL (20 cases) and LGSIL (19 cases)
diagnoses were also confirmed by histopathology. There
was no significant difference in mean age ± SD between
cervical cancer patients (51.55 ± 14.55), HGSIL patients
(41.29 ± 10.89), LGSIL patients (38.52 ± 9.72) and con-
trols (44.10 ± 9.56).
Peripheral blood NK cell percentage was not significantly





   Sample Lysis  Basal lysis)= × −
−
100
100  Basal Lysis
Table 1: Primer sequences for HPV typification




(DNA) – CGTCCAAGAGGATACTGATC 1F
(DNA) – GCACAGGGTCATAATAATGG 1R
188
HVP6/11 (DNA) – CTCTGCCGGTGGTCAGTGCAT 1F
(DNA) – ATGCCTCCACGTCTGCAAC 1R
120
HVP16 (DNA) – CTGCACATGGGTGTGTGC 1F
(DNA) – GCAGCTCTGTGCATAAC 1R
229
HVP18 (DNA) – GAATTCACTCTATGTGCAG 1F
(DNA) – TAGTTGTTGCCTGTAGGTG 1R
221
HVP31 (DNA) – TTCAAAAATCCTGCAGAAAG 1F
(DNA) – CTTTGACACGTTATACACCT 1R
320
HVP33 (DNA) – ACCTTTGCAACGATCTGAGG 1F
(DNA) – GAACCGCAAACACAGTTTAC 1R
108
* w = a or t; s = c or g; y = c or tPage 3 of 8
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3.41, respectively). However, patients with cervical cancer
had significantly lower NK cell percentage (10.47 ± 3.58)
in comparison with HGSIL patients (p < 0.05).
Low NKp30, NKp46 and NKG2D expression on NK cells 
from patients with cervical cancer and HGSIL
We analyzed by flow cytometry the NCR (NKp30 and
NKp46) phenotype (dull or bright), NKp30, NKp46 and
NKG2D-expressing cells and MFI was also evaluated.
Most healthy donors (90%) and patients with LGSIL
(85%) had NK cells with NKp30Bright and NKp46bright phe-
notype. Patients with HGSIL had NK cells with
NKp30bright and NKp46bright phenotype of 50%. In con-
trast, only 30% of patients with invasive cervical carci-
noma showed NKp30bright and NKp46bright phenotype. We
observed a significant decrease in NKp30 and NKp46 MFI
on NK cells obtained from cervical cancer patients and
HGSIL in comparison with healthy women and LGSIL
patients (Figure 1). NKp30 and NKp46 expression (MFI)
showed a significant negative correlation with HPV-16
infection (r = -0.508., p = 0.05). We did not find any sig-
nificant correlation between NKp30 and NKp46 expres-
sion and other HPV types infection. Spearman's
Correlation Coefficient between stage and NKp30 and
NKp46 expression (MFI) showed a significant negative
correlation (r = -0.774, p = 0.01).
We also found a significant lower expression of NKG2D
on NK cells from cervical cancer patients in comparison
with healthy women (p < 0.05). There was not a signifi-
cant difference with HGSIL and LGSIL patients (Figure 1).
Expression of co-receptors 2B4 and NKp80 in NK cells
Expression of co-receptors 2B4 and NKp80 (MFI) on NK
cells was not significantly different between cervical can-
cer, HGSIL, LGSIL and healthy groups (Figure 2).
Low cytotoxic activity in NK cells from cervical cancer and 
HGSIL patients
NK cell-mediated specific cell lysis was decreased accord-
ing to the natural history of cervical cancer: healthy
women > LGSIL > HGSIL > cervical cancer (Figure 3). NK
cell activity was significantly lower in patients with cervi-
cal carcinoma at all E/T ratios in comparison with LGSIL
patients and healthy women (p < 0.0001). NK cell activity
was also significantly decreased in HGSIL patients at 10:1
and 30:1 E/T ratios (p < 0.02) in comparison with LGSIL
patients and healthy women (Figure 3). Percentage of spe-
cific lysis was correlated with NKp30 and NKp46 MFI. We
found a significant correlation with NKp30 at 10:1 ratio (r
= 0.686, p < 0.001) and at 30:1 ratio (r = 0.749, p < 0.001).
We also found a significant correlation with NKp46 at
10:1 ratio (r = 0.468, p < 0.05) and at 30:1 ratio (r = 0.658,
p < 0.01).
Discussion
It has been proposed that immunosurveillance escape
might be the seventh hallmark of cancer [17]. Intricate
interactions between tumor and immune cells take place
within the tumor microenvironment. These complex
processes (often unknown) result in either tumor destruc-
tion (elimination phase), equilibrium phase or tumor
growth (escape phase) by sculpting immunogenic cancer
cells. Experimental and clinical evidence suggests that edi-
tion process dictates the immune response within tumor
microenvironment. Cervical cancer represents an excel-
lent opportunity to study the immune response and eva-
sion mechanisms from precursor lesions to invasive
carcinoma. NK cells play a crucial role in tumor immuno-
surveillance [13]. Arguments that may point to an impor-
tant role of NK cells in the natural history of cervical
cancer are: a) NK cells can recognize and either destroy
virally infected cells or control the infection via cytokines
(IFN-gamma and TNF-alpha), b) HPV-associated cervical
tumors frequently exhibit a reduction in MHC class I
expression as an immune evasion strategy, c) NK cell
receptor ligands (MICA and CD155) are differentially
expressed during progression to cervical cancer
[15,18,19]. However, the biological significance of NK
cells on HPV infection, viral persistence, SIL progression
and invasion has not been addressed.
In this article we examined NKp30, NKp46, NKG2D,
NKp80 and 2B4 expression in NK cells from patients with
cervical cancer and precursor lesions, in the context of NK
cell cytolytic activity and HPV infection. We report here
for the first time that the NK cell-activating receptors
NKp30 and NKp46 are significantly down-regulated in
cervical cancer patients and HGSIL. Our results are con-
sistent with previous reports in patients with myelocytic/
monocytic acute myeloid leukemia. NK cells from such
patients exhibit poor cytolytic functions due to deficient
expression of NKp30, NKp44, and NKp46 receptors [20].
Myelodysplastic syndromes have reduced activating NK
cell receptors (NKG2D and NKp30) in association with
disease progression to myeloid leukemia [21]. It has been
reported that NCR expression on NK cells correlates with
the ability to lyse tumor cells [22]. NKp30 and NKp46 are
the major NCRs against tumors. On the other hand, NK
cell-mediated killing of HeLa cells was not significantly
reduced with anti-NKp44 as seen with anti-NKp30 [23].
Our findings suggest a clinically relevant role of NCRs in
cervical cancer progression, because low NKp30 and
NKp46 expressions were correlated with diminished NK
cell activity, HPV-16 infection and clinical stage. While
the statistical correlation between diminished receptor
expression and diminished specific lysis is strong, we can-
not rule out the possibility that other mechanisms, such as
lowered adhesin binding or decreased perforin B/Page 4 of 8
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NCRs and NKG2D expression are decreased in NK cells from cervical cancer patientsFigure 1
NCRs and NKG2D expression are decreased in NK cells from cervical cancer patients. NKp30, NKp46 and 
NKG2D expression was analyzed by flow cytometry on NK cells from patients with cervical cancer (20 cases), HGSIL (20 
cases), LGSIL (19 cases) and 20 healthy women. MFI was expressed as mean ± SD. A) NKp30; B) NKp46: * HGSIL versus LGSIL 
and healthy women p < 0.02, ** Invasive Ca versus LGSIL and healthy women p < 0.0001; C) NKG2D: * Invasive Ca versus 
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2B4 and NKp80 co-receptor expression is not down-regulated on NK cells from cervical cancer patientsFigure 2
2B4 and NKp80 co-receptor expression is not down-regulated on NK cells from cervical cancer patients. 2B4 
and NKp80 expression was analyzed by flow cytometry on NK cells from patients with cervical cancer (20 cases), HGSIL (20 
cases), LGSIL (19 cases) and 20 healthy women. MFI was expressed as the mean ± SD. A) 2B4; B) NKp80; and C) Two repre-




























NK cell specific lysis is decreased according to the natural history of cervical cancer: healthy women (6 controls) > LGSIL (6 cases) > HGSIL (5 cases) > cervic l ancer (5 cas s)Figure 3
NK cell specific lysis is decreased according to the natural history of cervical cancer: healthy women (6 con-
trols) > LGSIL (6 cases) > HGSIL (5 cases) > cervical cancer (5 cases). NK cell cytotoxicity against K562 cells was 
evaluated in a 4 hour CFSE/7-AAD flow cytometry assay against K562 tumor line. Significant difference at 10:1 and 30:1 E:T 
























BMC Cancer 2009, 9:186 http://www.biomedcentral.com/1471-2407/9/186granzyme activity might be operating in the reduction of
specific lysis. To clarify this point, future experiments
looking at changes of other molecules might be war-
ranted. It is important to extend our findings using cervi-
cal cancer cell lines and fresh cervical cancer cells as
targets. NCR ligands are still unknown, but by using solu-
ble NCR fusion proteins the existence of NCR ligands on
several tumor cells has been documented. Direct analysis
of the expression of NKp30L and NKp40L on Hela cells (a
cervical cancer cell line) revealed intracellular and extra-
cellular expression of both ligands, wich was linked to
NKp30-dependent lysis [23].
In this study we also found that the NK cell-activating
receptor NKG2D is significantly down-regulated in cervi-
cal cancer patients. This result is consistent with a previous
study reporting a significant decrease in the number of
NKG2D-expressing NK and T cells in both cervical cancer
and precursor lesion patients. However, they only found a
significant correlation between high soluble MICA levels
and low NKG2D in T cells [24].
NCRs and NKG2D may be down-regulated by different
molecules and mechanisms such as TGF-beta, indoleam-
ine 2,3-dioxygenase, prostaglandin E2, corticosteroids, 17
beta-estradiol and reactive oxygen species [25-29]. We do
not know yet the precise mechanism that underlies
NKp30, NKp46 and NKG2D down-regulation in NK cells
from cervical cancer patients; however, it has been
reported that TGF-beta1 mRNA overexpression is associ-
ated with progression from LGSIL to HGSIL [30,31]. TGF-
beta is also upregulated at least two-fold in lymph node
cervical cancer micrometastases [32]. Indoleamine 2,3-
dioxygenase was also found at the invasion front of inva-
sive cervical tumors and peritumoral stromal cells [33]. In
the present work we found that NKp30 and NKp46 dimi-
nution was linked to HPV-16 infection. HPV-16 oncopro-
teins E6 and E7 down-modulate IFN-gamma and IL-18
response [34]. Other studies suggest that HPV infection
affects dendritic cell migration and function [35,36]. We
recently reported that CEACAM1, an adhesion molecule
with NK cell inhibitory properties, is up-regulated in
HGSIL linked to HPV-16 infection [37].
Taken together our results and previous reports suggest
that NKp30, NKp46 and NKG2D down-regulation repre-
sent an evasion mechanism associated with low NK cell
activity, HPV-16 infection and cervical cancer progression.
Our findings may be important for development of new
therapeutic strategies, for example the use of NCR-Ig
fusion proteins with aim of inhibit tumor growth [38].
Conclusion
Our results suggest that NKp30, NKp46 and NKG2D
down-regulation represent an evasion mechanism associ-
ated with low NK cell activity, HPV-16 infection and cer-
vical cancer progression.
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